Biomarker Insights (Jun 2021)

Effect of Methylprednisolone on Inflammation and Coagulation in Patients with Severe COVID-19: A Retrospective Cohort Study

  • Katja Tromp,
  • Philip van der Zee,
  • Casper Rokx,
  • Jeroen van Kampen,
  • Diederik Gommers,
  • Henrik Endeman

DOI
https://doi.org/10.1177/11772719211021647
Journal volume & issue
Vol. 16

Abstract

Read online

Corticosteroids reduced mortality rate in patients with coronavirus disease 2019 (COVID-19). Previously, we hypothesized that corticosteroids mitigate the inflammation response resulting in reduced coagulation and thrombosis. In this retrospective study, we included 27 patients with COVID-19 that received high-dose corticosteroids (methylprednisolone 1000 mg i.v. daily for 3 days) for persistent respiratory failure or an excessive inflammation response. We found that inflammation, coagulation, and ventilation parameters improved significantly after methylprednisolone. The viral loads of SARS-CoV-2 remained stable or decreased. These results provides insight into the reduced mortality rate observed in patients with COVID-19 treated with corticosteroids.